BMO Capital Reiterates BioMarin (BMRN) at Outperform: unique opportunity to buy the dip and can attract M&A interest
Tweet Send to a Friend
BMO Capital analyst Kostas Biliouris reiterated an Outperform rating and $115.00 price target on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN).The analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
